Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...

Patients with obesity often report being shamed and stigmatized in medical settings. How can physicians address weight ...

Made in the USA, a new daily oral weight-loss pill from Eli Lilly won't require cold storage and is expected to hit markets in 2026. It reportedly works as well as Ozempic.

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Eli Lilly said in February that it will invest at least $27 billion to build four new manufacturing sites in the U.S. as ...

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

If approved, the pill is expected to be far easier to administer than current injectables — and far easier to manufacture.

The Big Money Show' panel discusses President Donald Trump's plan to bring drug manufacturing back to the U.S.

The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any ...

Lilly's announcement that it would make its experimental weight-loss pill in the U.S. comes amid administration pressure on ...